Search

The challenge of enteric fever

Enteric fever prevention requires significant long term investment in provision of clean water and sanitation; vaccination offers medium term control.

Lowering Australia's defence against infectious diseases

Australia's defence, infectious diseases

AuTOmatic: Adaptive Trial of MessAging to improve Immunisation Coverage

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

BEAT-CF: Bayesian Evidence-Adaptive Tool to optimise management of Cystic Fibrosis

An innovative response-adaptive approach to driving improvements in health outcomes, applied to cystic fibrosis.

Determinants of incomplete vaccination and non-vaccination among WA children

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Evaluation of PLATINUM C: PLATform IN the Use of Medicines to treat chronic hepatitis C

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

FeBRILe3– Fever, Blood cultures and Readiness for discharge in Infants Less than 3 months’ old

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Professor Tom Snelling

Head, Infectious Disease Implementation Research

Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.

FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months Old

Evidence-based recommendations exist for early discharge (before 48 h) of young infants with fever without source (FWS) at low risk of serious bacterial infections (SBIs). However, concerns regarding the applicability of international data to local contexts may hinder implementation. We aimed to describe the local epidemiology of FWS and evaluate a newly implemented risk-stratification guideline to support practice change.